oncgnostics develops - based on proprietary epigenetic biomarkers - highly reliable molecular in-vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in oncology.
Molecular diagnostics company oncgnostics GmbH closes Series A financing round for CE mark and market entry of its cervical cancer diagnostics test GynTect®
oncgnostics develops, based on proprietary epigenetic biomarkers molecular tests for reliable cancer diagnostics. With the seed financing through High-tech Gruenderfonds (HTGF) and Stiftung fuer Technologie, Innovation und Forschung Thueringen (STIFT), oncgnostics implemented a quality management system and developed…
High-Tech Gründerfonds and STIFT invest into molecular cancer diagnostics from Jena
Oncgnostics GmbH obtains seed funding for financing preclinical and clinical trials. Chemical alterations of the genetic information specifically occuring during carcinogenesis provide the basis for the innovative diagnostic tests that are developed by the newly established oncgnostics GmbH in Jena. These tests allow…
Winzerlaer Straße 2
13. Mar 2012